The University of Navarra and the company 3P Biopharmaceuticals will promote research and talent management in technology and the production of new drugs.
News and updates
Partnerships & Collaborations
Annexin and Biovian have successfully completed ANXV manufacturing
Affibody AB has selected Biovian as a CDMO partner for their novel therapeutic protein candidate, ABY-062.
Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
3P Biopharmaceuticals and Invizius hope for reducing the cardiovascular complications associated with dialysis
3P Biopharmaceuticals and SpyBiotech enter into a Vaccine cGMP Manufacturing Agreement
Biovian signs an agreement about early-stage development and manufacturing of a COVID-19 vaccine candidate.
Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)